- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The World Health Assembly, convened annually by WHO at the UN Palais des Nations in Geneva, passed a resolution in May 2014 approving with full support the new post-2015 Global TB Strategy with its ambitious targets. The strategy aims to end the global TB epidemic, with targets to reduce TB deaths by 95% and to cut new cases by 90% between 2015 and 2035, and to ensure that no family is burdened with catastrophic expenses due to TB. It sets interim milestones for 2020, 2025, and 2030.
The 2013-2016 Laboratory Network Strategic Plan (LNSP) is a sub-plan of the 2010-2016 Philippine Plan of Action to Control Tuberculosis (PhilPACT). This plan will serve as a roadmap to strengthen the network’s laboratory services to control TB. It is aligned with various existing strategic plans to improve the laboratory facilities and activities in the country.
This discussion paper on gender and TB is intended to support practitioners, civil society and government partners wishing to make the investment case for increased and improved TB programming that addresses the specific vulnerabilities and needs of both men and women who are living with or at risk of TB. The paper summarizes the existing evidence base, demonstrating the ways in which gender has an impact on the risks and effects of TB (including those that intersect with HIV), and highlighting existing gaps in data and implementation. This information is useful for UNDP in its role in supporting governments to implement and operationalize the development agenda by 2030, by turning commitments into action.
Keywords: HIV, TB, deaths, women, men, mother, children, pregnant, infants
The Essentials provides in-depth explanations of the vision, goal, targets and milestones of the End TB Strategy as well as the key indicators to measure progress. It then outlines the essential features of operationalizing the principles, pillars and components of the End TB Strategy. Country experiences are included throughout as examples in applying elements of the strategy.
The Essentials is organized in three parts: Part I presents the overall approach, principles and the first steps of implementation expected at the country level. Part II explains the vision, goal, indicators, targets and milestones of the Strategy and Part III outlines the policies, the actors and actions needed to help implement the new approaches laid out under the three pillars of the Strategy: (i) Integrated, patient-centred care and prevention; (ii) Bold policies and supportive systems; and (iii) Intensified research and innovation.
In Hong Kong, extrapulmonary TB and, at CD4 count <200/μL,pulmonary TB and TB of cervical lymph node are AIDS-defining conditions. From 1996 to 2012, 358 (26.5%) of reported AIDS were defined primarily by TB. In 2005 and 2007, it briefly overtook Pneumocystis jiroveci pneumonia as the most common AIDS-defining condition. It is estimated that 1% of all TB disease in Hong Kong is associated with HIV. The corresponding figure in the US is 8%.
World leaders are meeting in Addis Ababa, Ethiopia for the UN Financing for Development Conference to discuss financing for the Sustainable Development Goals (SDGs), a new set of global development targets. The draft SDG goals include a target to end the epidemic of tuberculosis by 2030, in line with the
Keywords: HIV, TB, domestic, financing, investment
The Global Plan 2016-2020 sets out the actions and resources needed over the next five years to set the world on a course to end the global TB epidemic by 2030, as endorsed by world leaders in the newly adopted Sustainable Development Goals.
This Plan makes it clear that what is needed to end TB is a paradigm shift - a change in the way we fight TB at every level, in every community, in every health facility, in every country.
The survey was primarily designed to assess the status of national policies in relation to the latest WHO recommendations in five key areas: diagnosis, models of care, treatment of drug-sensitive (DS) TB, treatment of drug-resistant (DR) TB, and the regulatory environment for TB drugs. Where possible, we attempted to assess the extent to which diagnostic policies have been successfully implemented, although this could only be done on a qualitative basis. This survey is a follow-up of the study conducted by MSF in 2014. This updated survey has a broader scope to survey more policy areas and expands the number of surveyed countries from 8 to 24.
This is the twentieth global report on tuberculosis (TB) published by WHO in a series that started in 1997. It provides a comprehensive and up-to-date assessment of the TB epidemic and progress in implementing and financing TB prevention, care, control and research at global, regional and country levels using data reported by over 200 countries that account for more than 99% of the world's TB cases. In this 2015 edition, particular attention is given to assessment of whether 2015 global TB targets set in the context of the Millennium Development Goals were achieved worldwide and at regional and country levels.
Tuberculosis (TB) is a significant global public health threat. Despite being preventable and curable, the disease is widespread. In 2013, 9 million people fell ill with TB and 1.5 million people died from the disease – including 360,000 people coinfected with HIV. An estimated 550,000 children became ill with TB. The burden of this disease is disproportionately borne by relatively few countries, primarily in the developing world, with the majority of the global TB burden, spread across 22 highburden countries.